Abstract
Summary
This report studies the Bacterial Vaginosis Drug market, Bacterial Vaginosis Drug is used for the treatment of Bacterial Vaginosis (BV), which also known as vaginal bacteriosis or Gardnerella vaginitis, a disease of the vagina caused by excessive bacteria. This report includes metronidazole, clindamycin drug and other drugs.
The global market for Bacterial Vaginosis Drug was estimated to be worth US$ 916.5 million in 2023 and is forecast to a readjusted size of US$ 1130 million by 2030 with a CAGR of 3.0% during the forecast period 2024-2030.
Global Bacterial Vaginosis Drug key players include Bayer, Pfizer, Sanofi, Piramal, Abbott, etc. Global top five manufacturers hold a share about 20%. North America and Europe is the largest market, both with a share about 30%, followed by China, with a share about 10 percent. In terms of product, OTC is the largest segment, with a share about 70%. And in terms of application, the largest application is Pharmacy, followed by Hospital, etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Bacterial Vaginosis Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyse their position in the current marketplace, and make informed business decisions regarding Bacterial Vaginosis Drug.
The Bacterial Vaginosis Drug market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Bacterial Vaginosis Drug market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Bacterial Vaginosis Drug companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Market Segmentation
By Company
Bayer
Pfizer
Sanofi
Piramal
Abbott
Galderma
Mission
Alkem
Xiuzheng
Teva
Perrigo
West-Ward
HPGC
Yunnan Baiyao
Starpharma
Novel
Edenvridge
Segment by Type
Rx
OTC
Segment by Application
Hospital
Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Bacterial Vaginosis Drug in global and regional level.
Chapter 3: Detailed analysis of Bacterial Vaginosis Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Bacterial Vaginosis Drug revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion
The global market for Bacterial Vaginosis Drug was estimated to be worth US$ 916.5 million in 2023 and is forecast to a readjusted size of US$ 1130 million by 2030 with a CAGR of 3.0% during the forecast period 2024-2030.
Global Bacterial Vaginosis Drug key players include Bayer, Pfizer, Sanofi, Piramal, Abbott, etc. Global top five manufacturers hold a share about 20%. North America and Europe is the largest market, both with a share about 30%, followed by China, with a share about 10 percent. In terms of product, OTC is the largest segment, with a share about 70%. And in terms of application, the largest application is Pharmacy, followed by Hospital, etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Bacterial Vaginosis Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyse their position in the current marketplace, and make informed business decisions regarding Bacterial Vaginosis Drug.
The Bacterial Vaginosis Drug market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Bacterial Vaginosis Drug market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Bacterial Vaginosis Drug companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Market Segmentation
By Company
Bayer
Pfizer
Sanofi
Piramal
Abbott
Galderma
Mission
Alkem
Xiuzheng
Teva
Perrigo
West-Ward
HPGC
Yunnan Baiyao
Starpharma
Novel
Edenvridge
Segment by Type
Rx
OTC
Segment by Application
Hospital
Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Bacterial Vaginosis Drug in global and regional level.
Chapter 3: Detailed analysis of Bacterial Vaginosis Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Bacterial Vaginosis Drug revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion
Table of Contents
1 Study Coverage
1.1 Bacterial Vaginosis Drug Product Introduction
1.2 Market by Type
1.2.1 Global Bacterial Vaginosis Drug Market Size Growth Rate by Type (2019 VS 2023 VS 2030)
1.2.2 Rx
1.2.3 OTC
1.3 Market by Application
1.3.1 Global Bacterial Vaginosis Drug Market Size Growth Rate by Application (2019 VS 2023 VS 2030)
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Bacterial Vaginosis Drug Market Size Estimates and Forecasts
2.2 Bacterial Vaginosis Drug Market Size by Region: 2023 Versus 2030
2.2.1 Global Bacterial Vaginosis Drug Revenue by Region: 2019-2024
2.2.2 Global Bacterial Vaginosis Drug Revenue Forecast by Region (2025-2030)
2.2.3 Global Bacterial Vaginosis Drug Revenue Market Share by Region (2019-2030)
3 Global Bacterial Vaginosis Drug by Company
3.1 Global Bacterial Vaginosis Drug Revenue by Company (2019-2024)
3.2 Global Bacterial Vaginosis Drug Revenue Share by Company (2019-2024)
3.3 Competitive Landscape
3.3.1 Key Bacterial Vaginosis Drug Companies around the World: Ranking by Revenue
3.3.2 Global Bacterial Vaginosis Drug Market Concentration Ratio (CR5 and HHI) & (2019-2024)
3.3.3 Global Bacterial Vaginosis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.4 Global Bacterial Vaginosis Drug Companies Headquarters & Product Type
3.4.1 Bacterial Vaginosis Drug Companies Headquarters
3.4.2 Global Bacterial Vaginosis Drug Companies Product & Service
3.4.3 Date of International Companies Enter into Bacterial Vaginosis Drug Market
3.5 Global Bacterial Vaginosis Drug Mergers & Acquisitions, Expansion Plans
4 Company Profiles
4.1 Bayer
4.1.1 Bayer Company Information
4.1.2 Bayer Description, Business Overview
4.1.3 Bayer Bacterial Vaginosis Drug Products Offered
4.1.4 Bayer Bacterial Vaginosis Drug Revenue and Gross Margin (2019-2024)
4.1.5 Bayer Bacterial Vaginosis Drug Revenue by Product in 2023
4.1.6 Bayer Bacterial Vaginosis Drug Revenue by Application in 2023
4.1.7 Bayer Bacterial Vaginosis Drug Revenue by Geographic Area in 2023
4.1.8 Bayer Recent Developments
4.2 Pfizer
4.2.1 Pfizer Company Information
4.2.2 Pfizer Description, Business Overview
4.2.3 Pfizer Bacterial Vaginosis Drug Products Offered
4.2.4 Pfizer Bacterial Vaginosis Drug Revenue and Gross Margin (2019-2024)
4.2.5 Pfizer Bacterial Vaginosis Drug Revenue by Product in 2023
4.2.6 Pfizer Bacterial Vaginosis Drug Revenue by Application in 2023
4.2.7 Pfizer Bacterial Vaginosis Drug Revenue by Geographic Area in 2023
4.2.8 Pfizer Recent Developments
4.3 Sanofi
4.3.1 Sanofi Company Information
4.3.2 Sanofi Description, Business Overview
4.3.3 Sanofi Bacterial Vaginosis Drug Products Offered
4.3.4 Sanofi Bacterial Vaginosis Drug Revenue and Gross Margin (2019-2024)
4.3.5 Sanofi Bacterial Vaginosis Drug Revenue by Product in 2023
4.3.6 Sanofi Bacterial Vaginosis Drug Revenue by Application in 2023
4.3.7 Sanofi Bacterial Vaginosis Drug Revenue by Geographic Area in 2023
4.3.8 Sanofi Recent Developments
4.4 Piramal
4.4.1 Piramal Company Information
4.4.2 Piramal Description, Business Overview
4.4.3 Piramal Bacterial Vaginosis Drug Products Offered
4.4.4 Piramal Bacterial Vaginosis Drug Revenue and Gross Margin (2019-2024)
4.4.5 Piramal Bacterial Vaginosis Drug Revenue by Product in 2023
4.4.6 Piramal Bacterial Vaginosis Drug Revenue by Application in 2023
4.4.7 Piramal Bacterial Vaginosis Drug Revenue by Geographic Area in 2023
4.4.8 Piramal Recent Developments
4.5 Abbott
4.5.1 Abbott Company Information
4.5.2 Abbott Description, Business Overview
4.5.3 Abbott Bacterial Vaginosis Drug Products Offered
4.5.4 Abbott Bacterial Vaginosis Drug Revenue and Gross Margin (2019-2024)
4.5.5 Abbott Bacterial Vaginosis Drug Revenue by Product in 2023
4.5.6 Abbott Bacterial Vaginosis Drug Revenue by Application in 2023
4.5.7 Abbott Bacterial Vaginosis Drug Revenue by Geographic Area in 2023
4.5.8 Abbott Recent Developments
4.6 Galderma
4.6.1 Galderma Company Information
4.6.2 Galderma Description, Business Overview
4.6.3 Galderma Bacterial Vaginosis Drug Products Offered
4.6.4 Galderma Bacterial Vaginosis Drug Revenue and Gross Margin (2019-2024)
4.6.5 Galderma Bacterial Vaginosis Drug Revenue by Product in 2023
4.6.6 Galderma Bacterial Vaginosis Drug Revenue by Application in 2023
4.6.7 Galderma Bacterial Vaginosis Drug Revenue by Geographic Area in 2023
4.6.8 Galderma Recent Development
4.7 Mission
4.7.1 Mission Company Information
4.7.2 Mission Description, Business Overview
4.7.3 Mission Bacterial Vaginosis Drug Products Offered
4.7.4 Mission Bacterial Vaginosis Drug Revenue and Gross Margin (2019-2024)
4.7.5 Mission Bacterial Vaginosis Drug Revenue by Product in 2023
4.7.6 Mission Bacterial Vaginosis Drug Revenue by Application in 2023
4.7.7 Mission Bacterial Vaginosis Drug Revenue by Geographic Area in 2023
4.7.8 Mission Recent Development
4.8 Alkem
4.8.1 Alkem Company Information
4.8.2 Alkem Description, Business Overview
4.8.3 Alkem Bacterial Vaginosis Drug Products Offered
4.8.4 Alkem Bacterial Vaginosis Drug Revenue and Gross Margin (2019-2024)
4.8.5 Alkem Bacterial Vaginosis Drug Revenue by Product in 2023
4.8.6 Alkem Bacterial Vaginosis Drug Revenue by Application in 2023
4.8.7 Alkem Bacterial Vaginosis Drug Revenue by Geographic Area in 2023
4.8.8 Alkem Recent Development
4.9 Xiuzheng
4.9.1 Xiuzheng Company Information
4.9.2 Xiuzheng Description, Business Overview
4.9.3 Xiuzheng Bacterial Vaginosis Drug Products Offered
4.9.4 Xiuzheng Bacterial Vaginosis Drug Revenue and Gross Margin (2019-2024)
4.9.5 Xiuzheng Bacterial Vaginosis Drug Revenue by Product in 2023
4.9.6 Xiuzheng Bacterial Vaginosis Drug Revenue by Application in 2023
4.9.7 Xiuzheng Bacterial Vaginosis Drug Revenue by Geographic Area in 2023
4.9.8 Xiuzheng Recent Development
4.10 Teva
4.10.1 Teva Company Information
4.10.2 Teva Description, Business Overview
4.10.3 Teva Bacterial Vaginosis Drug Products Offered
4.10.4 Teva Bacterial Vaginosis Drug Revenue and Gross Margin (2019-2024)
4.10.5 Teva Bacterial Vaginosis Drug Revenue by Product in 2023
4.10.6 Teva Bacterial Vaginosis Drug Revenue by Application in 2023
4.10.7 Teva Bacterial Vaginosis Drug Revenue by Geographic Area in 2023
4.10.8 Teva Recent Development
4.11 Perrigo
4.11.1 Perrigo Company Information
4.11.2 Perrigo Description, Business Overview
4.11.3 Perrigo Bacterial Vaginosis Drug Products Offered
4.11.4 Perrigo Bacterial Vaginosis Drug Revenue and Gross Margin (2019-2024)
4.11.5 Perrigo Bacterial Vaginosis Drug Revenue by Product in 2023
4.11.6 Perrigo Bacterial Vaginosis Drug Revenue by Application in 2023
4.11.7 Perrigo Bacterial Vaginosis Drug Revenue by Geographic Area in 2023
4.11.8 Perrigo Recent Development
4.12 West-Ward
4.12.1 West-Ward Company Information
4.12.2 West-Ward Description, Business Overview
4.12.3 West-Ward Bacterial Vaginosis Drug Products Offered
4.12.4 West-Ward Bacterial Vaginosis Drug Revenue and Gross Margin (2019-2024)
4.12.5 West-Ward Bacterial Vaginosis Drug Revenue by Product in 2023
4.12.6 West-Ward Bacterial Vaginosis Drug Revenue by Application in 2023
4.12.7 West-Ward Bacterial Vaginosis Drug Revenue by Geographic Area in 2023
4.12.8 West-Ward Recent Development
4.13 HPGC
4.13.1 HPGC Company Information
4.13.2 HPGC Description, Business Overview
4.13.3 HPGC Bacterial Vaginosis Drug Products Offered
4.13.4 HPGC Bacterial Vaginosis Drug Revenue and Gross Margin (2019-2024)
4.13.5 HPGC Bacterial Vaginosis Drug Revenue by Product in 2023
4.13.6 HPGC Bacterial Vaginosis Drug Revenue by Application in 2023
4.13.7 HPGC Bacterial Vaginosis Drug Revenue by Geographic Area in 2023
4.13.8 HPGC Recent Development
4.14 Yunnan Baiyao
4.14.1 Yunnan Baiyao Company Information
4.14.2 Yunnan Baiyao Description, Business Overview
4.14.3 Yunnan Baiyao Bacterial Vaginosis Drug Products Offered
4.14.4 Yunnan Baiyao Bacterial Vaginosis Drug Revenue and Gross Margin (2019-2024)
4.14.5 Yunnan Baiyao Bacterial Vaginosis Drug Revenue by Product in 2023
4.14.6 Yunnan Baiyao Bacterial Vaginosis Drug Revenue by Application in 2023
4.14.7 Yunnan Baiyao Bacterial Vaginosis Drug Revenue by Geographic Area in 2023
4.14.8 Yunnan Baiyao Recent Development
4.15 Starpharma
4.15.1 Starpharma Company Information
4.15.2 Starpharma Description, Business Overview
4.15.3 Starpharma Bacterial Vaginosis Drug Products Offered
4.15.4 Starpharma Bacterial Vaginosis Drug Revenue and Gross Margin (2019-2024)
4.15.5 Starpharma Bacterial Vaginosis Drug Revenue by Product in 2023
4.15.6 Starpharma Bacterial Vaginosis Drug Revenue by Application in 2023
4.15.7 Starpharma Bacterial Vaginosis Drug Revenue by Geographic Area in 2023
4.15.8 Starpharma Recent Development
4.16 Novel
4.16.1 Novel Company Information
4.16.2 Novel Description, Business Overview
4.16.3 Novel Bacterial Vaginosis Drug Products Offered
4.16.4 Novel Bacterial Vaginosis Drug Revenue and Gross Margin (2019-2024)
4.16.5 Novel Bacterial Vaginosis Drug Revenue by Product in 2023
4.16.6 Novel Bacterial Vaginosis Drug Revenue by Application in 2023
4.16.7 Novel Bacterial Vaginosis Drug Revenue by Geographic Area in 2023
4.16.8 Novel Recent Development
4.17 Edenvridge
4.17.1 Edenvridge Company Information
4.17.2 Edenvridge Description, Business Overview
4.17.3 Edenvridge Bacterial Vaginosis Drug Products Offered
4.17.4 Edenvridge Bacterial Vaginosis Drug Revenue and Gross Margin (2019-2024)
4.17.5 Edenvridge Bacterial Vaginosis Drug Revenue by Product in 2023
4.17.6 Edenvridge Bacterial Vaginosis Drug Revenue by Application in 2023
4.17.7 Edenvridge Bacterial Vaginosis Drug Revenue by Geographic Area in 2023
4.17.8 Edenvridge Recent Development
5 Breakdown Data by Type
5.1 Global Bacterial Vaginosis Drug Revenue by Type (2019-2024)
5.2 Global Bacterial Vaginosis Drug Revenue Forecast by Type (2025-2030)
5.3 Bacterial Vaginosis Drug Revenue Market Share by Type (2019-2030)
6 Breakdown Data by Application
6.1 Global Bacterial Vaginosis Drug Revenue by Application (2019-2024)
6.2 Global Bacterial Vaginosis Drug Revenue Forecast by Application (2025-2030)
6.3 Bacterial Vaginosis Drug Revenue Market Share by Application (2019-2030)
7 North America
7.1 North America Bacterial Vaginosis Drug Market Size YoY Growth 2019-2030
7.2 North America Bacterial Vaginosis Drug Market Facts & Figures by Country (2019-2030)
7.3 North America Bacterial Vaginosis Drug Revenue by Type (2019-2024)
7.4 North America Bacterial Vaginosis Drug Revenue by Application (2019-2024)
8 Asia-Pacific
8.1 Asia-Pacific Bacterial Vaginosis Drug Market Size YoY Growth 2019-2030
8.2 Asia-Pacific Bacterial Vaginosis Drug Market Facts & Figures by Region (2019-2030)
8.3 Asia-Pacific Bacterial Vaginosis Drug Revenue by Type (2019-2024)
8.4 Asia-Pacific Bacterial Vaginosis Drug Revenue by Application (2019-2024)
9 Europe
9.1 Europe Bacterial Vaginosis Drug Market Size YoY Growth 2019-2030
9.2 Europe Bacterial Vaginosis Drug Market Facts & Figures by Country (2019-2030)
9.3 Europe Bacterial Vaginosis Drug Revenue by Type (2019-2024)
9.4 Europe Bacterial Vaginosis Drug Revenue by Application (2019-2024)
10 Latin America
10.1 Latin America Bacterial Vaginosis Drug Market Size YoY Growth 2019-2030
10.2 Latin America Bacterial Vaginosis Drug Market Facts & Figures by Country (2019-2030)
10.3 Latin America Bacterial Vaginosis Drug Revenue by Type (2019-2024)
10.4 Latin America Bacterial Vaginosis Drug Revenue by Application (2019-2024)
11 Middle East and Africa
11.1 Middle East and Africa Bacterial Vaginosis Drug Market Size YoY Growth 2019-2030
11.2 Middle East and Africa Bacterial Vaginosis Drug Market Facts & Figures by Country (2019-2030)
11.3 Middle East and Africa Bacterial Vaginosis Drug Revenue by Type (2019-2024)
11.4 Middle East and Africa Bacterial Vaginosis Drug Revenue by Application (2019-2024)
12 Supply Chain and Sales Channel Analysis
12.1 Bacterial Vaginosis Drug Supply Chain Analysis
12.2 Bacterial Vaginosis Drug Key Raw Materials and Upstream Suppliers
12.3 Bacterial Vaginosis Drug Clients Analysis
12.4 Bacterial Vaginosis Drug Sales Channel and Sales Model Analysis
12.4.1 Bacterial Vaginosis Drug Distribution Channel Analysis: Indirect Sales VS Direct Sales
12.4.2 Bacterial Vaginosis Drug Distribution Channel Analysis: Online Sales VS Offline Sales
12.4.3 Bacterial Vaginosis Drug Distributors
13 Market Dynamics
13.1 Bacterial Vaginosis Drug Industry Trends
13.2 Bacterial Vaginosis Drug Market Drivers
13.3 Bacterial Vaginosis Drug Market Challenges
13.4 Bacterial Vaginosis Drug Market Restraints
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer